The EU Commission clears a merger subject to remedies on the pharmaceutical market (Actelion / Johnson & Johnson)

Mergers: Commission approves acquisition of Actelion by Johnson & Johnson, subject to conditions* The European Commission has approved under the EU Merger Regulation the proposed acquisition of Actelion Pharmaceuticals by Johnson & Johnson. The decision is subject to conditions ensuring that clinical development of their innovative insomnia drugs will not be adversely affected by the merger. Commissioner Margrethe Vestager, responsible for competition policy commented: “Effective competition is important to stimulate research and development of innovative drugs, to the benefit of patients and our healthcare systems. Our decision makes sure that the development of innovative insomnia drugs will continue following the Johnson & Johnson and Actelion merger". Commission

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears a merger subject to remedies on the pharmaceutical market (Actelion / Johnson & Johnson), 9 June 2017, e-Competitions Bulletin June 2017, Art. N° 84315

Visites 66

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues